ALNYLAM GRANTS GENECARE RESEARCH INSTITUTE LICENSES TO FUNDAMENTAL INTELLECTUAL PROPERTY FOR RNAi THERAPEUTICS DIRECTED AGAINST TWO GENE TARGETS

Alnylam Pharmaceuticals, a leading therapeutic RNA interference (RNAi) company, has granted GeneCare Research Institute, a Japanese biotechnology firm, an exclusive license through the InterfeRx licensing program to discover, develop and commercialize RNAi therapeutics directed against two DNA helicase genes associated with cancer. Detailed financial terms were not disclosed, but include upfront, annual and milestone payments, all in cash, and royalties on sales of any products that result from the licensing agreement.

Yahoo News (http://biz.yahoo.com/prnews/050106/nyth051_1.html)